8-K

                                  UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                 CURRENT REPORT

     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


                                OCTOBER 23, 2008
                                ----------------
              Date of Report (Date of the earliest event reported)


                             SIMULATIONS PLUS, INC.
                             ----------------------
              Exact name of registrant as specified in its charter


     CALIFORNIA                     001-32046                   95-4595609
- ----------------------        ----------------------       ---------------------
State of Incorporation        Commission File Number           IRS Employer
                                                           Identification Number

            42505 10TH STREET WEST, LANCASTER, CALIFORNIA 93534-7059
            --------------------------------------------------------
           Address of principal executive offices, including zip code

                                  661-723-7723
                                  ------------
               Registrant's telephone number, including area code


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[_] Written communications pursuant to Rule 425 under the Security Act (17 CFR
230.425)

[_] Soliciting material pursuant to Rule 14a-12 under the exchange Act (17 CFR
240.14a-12)

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d -2(b))

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))





ITEM 8.01         OTHER EVENTS.

         On October 23, 2008, Simulations Plus, Inc., a California corporation
(the "Company" or "us," "our" or "we"), issued a press release announcing a
share repurchase program. A copy of the press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.

         The board of directors has authorized a share repurchase program
enabling the buyback of up to $2.5 million of our shares during a 12-month
period beginning Monday, October 27, 2008. The Company has opened an account
with Citigroup Smith Barney for the purchase of such securities. Funds for any
stock purchases will be drawn from the Company's then-current cash reserves.

         In implementing a share repurchase program, the Company will comply
with the safe harbor provisions contained in Rule 10b-18 under the Securities
and Exchange Act of 1934, as amended. Rule 10b-18, as such rule may be amended
in the future, shall take precedence over the terms of this program to the
extent any conflict should exist or arise in the future.

         This report on Form 8-K (the "Report"), including the disclosures set
forth herein and exhibits attached hereto, contains certain forward-looking
statements that involve substantial risks and uncertainties. When used herein,
the terms "anticipates," "expects," "estimates," "believes" and similar
expressions, as they relate to us or our management, are intended to identify
such forward-looking statements.

         Forward-looking statements in this Report or hereafter, including in
other publicly available documents filed with the Securities and Exchange
Commission (the "Commission"), reports to the stockholders of the Company and
other publicly available statements issued or released by us involve known and
unknown risks, uncertainties and other factors which could cause our actual
results, performance (financial or operating) or achievements to differ from the
future results, performance (financial or operating) or achievements expressed
or implied by such forward-looking statements. Such future results are based
upon management's best estimates based upon current conditions and the most
recent results of operations. These risks include, but are not limited to, the
risks set forth herein and in such other documents filed with the Commission,
each of which could adversely affect our business and the accuracy of the
forward-looking statements contained herein. Our actual results, performance or
achievements may differ materially from those expressed or implied by such
forward-looking statements.


ITEM 9.01         FINANCIAL STATEMENTS AND EXHIBITS

(c)      Exhibits

                  99.1     Press release dated October 23, 2008.








                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                        SIMULATIONS PLUS, INC.



Dated: October 23, 2008                 By: /s/ Momoko Beran
                                            --------------------
                                            Momoko Beran
                                            Chief Financial Officer






                                  EXHIBIT INDEX

Exhibit
Number                    Description

99.1              Press release dated October 23, 2008.

EX-99.1

EXHIBIT 99.1


SIMULATIONS PLUS
Integrating Science and Software

For Further Information:
SIMULATIONS PLUS, INC.
42505 10th Street West
Lancaster, CA 93534-7059

CONTACT:
Investor Relations
- ------------------
Ms. Renee Bouche
Simulations Plus, Inc.
661.723.7723
info@simulations-plus.com

For Immediate Release:

October 23, 2008

               SIMULATIONS PLUS ANNOUNCES SHARE REPURCHASE PROGRAM

       UP TO $2.5 MILLION OVER 12 MONTHS AUTHORIZED BY BOARD OF DIRECTORS

LANCASTER, CA, OCTOBER 23, 2008 - Simulations Plus, Inc. (Nasdaq: SLP), the
leading provider of simulation and modeling software for pharmaceutical
discovery and development, announced today that its board of directors has
authorized a share repurchase program effective Monday, October 27, 2008.

Ms. Momoko Beran, chief financial officer of Simulations Plus, said: "The board
of directors has authorized a share repurchase program enabling the buyback of
up to $2.5 million in shares during a 12-month period beginning Monday, October
27, 2008. Repurchases may be made in the open market, through a broker, or
through privately negotiated transactions, subject to market conditions,
applicable legal requirements and other factors. Simulations Plus has no
obligation to repurchase shares under the repurchase program and the timing,
actual number, and price of shares to be purchased will depend on the
performance of Simulations Plus' stock price, general market conditions, and
various other factors. Such purchases, if any, will be made in accordance with
applicable insider trading and other securities laws and regulations within the
discretion of management."

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added:
"At this time, the board believes that the undervaluation of our stock has
become so severe, and our accumulation of cash has continued so well, that using
some of it for this purpose is warranted, subject to management's discretion and
market conditions as Ms. Beran has described. Authorizing this amount is not
expected to interfere with potential acquisitions or with meeting operating
requirements, which the board believes are of utmost priority."

ABOUT SIMULATIONS PLUS, INC.

Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery
and development simulation software, which is licensed to and used in the
conduct of drug research by major pharmaceutical and biotechnology companies
worldwide. We have two other businesses that are based on our proprietary
technologies: a wholly owned subsidiary, Words+, Inc., which provides assistive
technologies to persons with disabilities; and an educational software series
for science students in middle and high schools known as FutureLab(TM). For more
information, visit our Web site at www.simulations-plus.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
- - With the exception of historical information, the matters discussed in this
press release are forward-looking statements that involve a number of risks and
uncertainties. The actual future results of the Company could differ
significantly from those statements. Factors that could cause or contribute to
such differences include, but are not limited to: the ability of the Company to
maintain its competitive advantage, the general economics of the pharmaceutical
industry, the ability of the Company to finance growth, and a sustainable
market. Further information on the Company's risk factors is contained in the
Company's quarterly and annual reports as filed with the Securities and Exchange
Commission.

                                       ###